Genome Editing Market

Genome Editing Market: Industry Trends and Global Forecast till 2035: Focus on Technology - Distribution by Type of Gene Editing Technique, Type of Therapy, Gene Editing Approach, Type of Gene Delivery Method, Gene Delivery Modality, Application Area, Type of End User, Key Geographical Regions and Distribution by Type of Payment Method Employed

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    458

  • Pages
    325

  • View Count
    10103

Table Of  Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
 
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
 
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS 
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
 
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
 
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
 
3.2.4. Recession
3.2.4.1. Historical Analysis of Past
Recessions and Lessons Learnt 
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
 
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
 
4. EXECUTIVE SUMMARY
 
5. INTRODUCTION
5.1. Chapter Overview
5.2. Introduction to Genome Editing
5.2.1. Evolution of Genome Editing
5.2.2. Genome Editing Technologies
5.2.2.1. CRISPR - Cas System
5.2.2.2. Transcription Activator-Like Effector Nucleases (TALENs)
5.2.2.3. Zinc Finger Nucleases (ZFNs)
5.2.2.4. Meganucleases / Homing Endonucleases
 
5.3. Applications of Genome Editing Technologies
5.4. Other Emerging Technologies
5.5. Concluding Remarks
 
6. TECHNOLOGY LANDSCAPE
6.1. Chapter Overview
6.2. Genome Editing: Technology Landscape
6.2.1. Analysis by Type of Gene Editing Technique
6.2.2. Analysis by Gene Editing Approach
6.2.3. Analysis by Type of Gene Delivery Method
6.2.4. Analysis by Type of Gene Delivery Modality
6.2.5. Analysis by Highest Phase of Drug Development Supported
6.2.6. Analysis by Therapeutic Area
6.2.7. Analysis by Application Area
 
6.3. Genome Editing: Technology Developer Landscape
6.3.1. Analysis by Year of Establishment
 
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.3.4. Analysis by Operational Model
6.3.5. Most Active Players: Distribution by Number of Technologies
 
7. TECHNOLOGY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Technology Competitiveness Analysis
7.4.1. Genome Editing Technologies Offered by Players based in North America
7.4.2. Genome Editing Technologies Offered by Players based in Europe
7.4.3. Genome Editing Technologies Offered by Players based in Asia-Pacific, Middle East and North Africa, and Latin America
 
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Arcturus Therapeutics
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Technology Portfolio
8.2.4. Recent Developments and Future Outlook
 
8.3. Beam Therapeutics
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Technology Portfolio
8.3.4. Recent Developments and Future Outlook
 
8.4. Caribou Biosciences
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Technology Portfolio
8.4.4. Recent Developments and Future Outlook
 
8.5. Century Therapeutics
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Technology Portfolio
8.5.4. Recent Developments and Future Outlook
 
8.6. CRISPR Therapeutics
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Technology Portfolio
8.6.4. Recent Developments and Future Outlook
 
8.7. Editas Medicine
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Technology Portfolio
8.7.4. Recent Developments and Future Outlook
 
8.8. Graphite Bio
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Recent Developments and Future Outlook
 
8.9. Intellia Therapeutics
8.9.1. Company Overview
8.9.2. Financial Information
8.9.3. Technology Portfolio
8.9.4. Recent Developments and Future Outlook
 
8.10. Prime Medicine
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Recent Developments and Future Outlook
 
8.11. Vor Biopharma
8.11.1. Company Overview
8.11.2. Technology Portfolio
8.11.3. Recent Developments and Future Outlook
 
8.12. Other Leading Players
8.12.1. Avectas
8.12.2. Bio-Sourcing
8.12.3. Edigene
8.12.4. Flash Therapeutics
8.12.5. Fortgen
8.12.6. G+FLAS Life Sciences
8.12.7. Ntrans Technologies
8.12.8. OXGENE
8.12.9. Revvity (formerly known as Horizon Discovery)
8.12.10. TargetGene Biotechnologies
8.12.11. ZeClinics
 
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Genome Editing Technologies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Location of Headquarters of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Analysis by Geography
9.3.7.1. Local and International Agreements
9.3.7.2. Intercontinental and Intracontinental Agreements
 
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Genome Editing Domain: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Type of Patent and Publication Year
10.3.3. Analysis by Geography
10.3.4. Analysis by CPC Symbols
10.3.5. Leading Industry Players: Analysis by Number of Patents
 
10.4. Genome Editing Domain: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.2. Analysis by Leading Industry Players
 
10.5. Patent Valuation Analysis
 
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Genome Editing Domain: Funding and Investment Analysis
11.3.1. Analysis by Year of Investment
11.3.1.1. Cumulative Year-wise Trend of Funding Instances
11.3.1.2. Cumulative Year-wise Trend of Amount Invested
 
11.3.2. Analysis by Type of Funding
11.3.2.1. Analysis of Funding Instances
11.3.2.2. Analysis of Amount Invested
11.3.3. Analysis by Year and Type of Funding
11.3.4. Analysis by Geography
11.3.5. Most Active Players: Analysis by Amount Invested and Number of Funding Instances
11.3.6. Leading Investors: Analysis by Number of Funding Instances
 
12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
12.1. Chapter Overview
12.2. Market Drivers
12.3. Market Restraints
12.4. Market Opportunities
12.5. Market Challenges
12.6. Conclusion
 
13. GENOME EDITING TECHNOLOGIES MARKET
13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Genome Editing Technologies Market, Forecasted Estimates (2023-2035)
13.3.1. Scenario Analysis
 
13.4. Key Market Segmentations
13.5. Dynamic Dashboard
 
14. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF GENE EDITING TECHNIQUE
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. CRISPR-Cas System: Forecasted Estimates (2023-2035)
14.4. TALENs: Forecasted Estimates (2023-2035)
14.5. Meganucleases: Forecasted Estimates (2023-2035)
14.6. ZFNs: Forecasted Estimates (2023-2035)
14.7. Other Techniques: Forecasted Estimates (2023-2035)
14.8. Data Triangulation
14.8.1. Insights from Primary Research
14.8.2. Insights from Secondary Research
14.8.3. Insights from In-house Repository
 
15. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF THERAPY
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Cell Therapies: Forecasted Estimates (2023-2035)
15.4. Gene Therapies: Forecasted Estimates (2023-2035)
15.5. Other Therapies: Forecasted Estimates (2023-2035)
15.6. Data Triangulation
15.6.1. Insights from Primary Research
15.6.2. Insights from Secondary Research
15.6.3. Insights from In-house Repository
 
16. GENOME EDITING TECHNOLOGIES MARKET, BY GENE EDITING APPROACH
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Gene Knock-Out Approaches: Forecasted Estimates (2023-2035)
16.4. Gene Knock-In Approaches: Forecasted Estimates (2023-2035)
16.5. Data Triangulation
16.5.1. Insights from Primary Research
16.5.2. Insights from Secondary Research
16.5.3. Insights from In-house Repository
 
17. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY METHOD
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Ex-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
17.4. In-Vivo Delivery Methods: Forecasted Estimates (2023-2035)
17.5. Data Triangulation
17.5.1. Insights from Primary Research
17.5.2. Insights from Secondary Research
17.5.3. Insights from In-house Repository
 
18. GENOME EDITING TECHNOLOGIES MARKET, BY GENE DELIVERY MODALITY
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Viral Vectors: Forecasted Estimates (2023-2035)
18.4. Non-Viral Vectors: Forecasted Estimates (2023-2035)
18.5. Data Triangulation
18.5.1. Insights from Primary Research
18.5.2. Insights from Secondary Research
18.5.3. Insights from In-house Repository
 
19. GENOME EDITING TECHNOLOGIES MARKET, BY APPLICATION AREA
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Drug Discovery and Development: Forecasted Estimates (2023-2035)
19.4. Diagnostics: Forecasted Estimates (2023-2035)
19.5. Data Triangulation
19.5.1. Insights from Primary Research
19.5.2. Insights from Secondary Research
19.5.3. Insights from In-house Repository
 
20. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF END USER
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Pharmaceutical and Biotechnology Companies: Forecasted Estimates (2023-2035)
20.4. Academic and Research Institutes: Forecasted Estimates (2023-2035)
20.5. Data Triangulation
20.5.1. Insights from Primary Research
20.5.2. Insights from Secondary Research
20.5.3. Insights from In-house Repository
 
21. GENOME EDITING TECHNOLOGIES MARKET, BY KEY GEOGRAPHICAL REGIONS
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. North America: Forecasted Estimates (2023-2035)
21.4. Europe: Forecasted Estimates (2023-2035)
21.5. Asia-Pacific: Forecasted Estimates (2023-2035)
21.6. Data Triangulation
21.6.1. Insights from Primary Research
21.6.2. Insights from Secondary Research
21.6.3. Insights from In-house Repository
 
22. GENOME EDITING TECHNOLOGIES MARKET, BY TYPE OF PAYMENT METHOD EMPLOYED
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Milestone Payments: Forecasted Estimates (2023-2035)
22.4. Upfront Payments: Forecasted Estimates (2023-2035)
22.5. Data Triangulation
22.5.1. Insights from Primary Research
22.5.2. Insights from Secondary Research
22.5.3. Insights from In-house Repository
 
23. GENOME EDITING TECHNOLOGIES MARKET: LEADING INDUSTRY PLAYERS 
23.1. Chapter Overview
23.2. Leading Industry Players
 
24. CONCLUSION
 
25. EXECUTIVE INSIGHTS
 
26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 4.1 Executive Summary: Technology Landscape
Figure 4.2 Executive Summary: Partnerships and Collaborations
Figure 4.3 Executive Summary: Patent Analysis
Figure 4.4 Executive Summary: Funding and Investment Analysis
Figure 4.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Genome Editing: Milestones Achieved in Gene Editing Domain
Figure 5.2 Types of Genome Editing Technologies
Figure 5.3 CRISPR / Cas System: Mechanism of Action
Figure 5.4 TALENs: Mechanism of Action
Figure 5.5 ZFNs: Mechanism of Action
Figure 5.6 Meganucleases / Homing Endonucleases: Mechanism of Action
Figure 5.7 Applications of Genome Editing Technologies
Figure 6.1 Genome Editing Technologies: Distribution by Type of Gene Editing Technique
Figure 6.2 Genome Editing Technologies: Distribution by Gene Editing Approach
Figure 6.3 Genome Editing Technologies: Distribution by Type of Gene Delivery Method
Figure 6.4 Genome Editing Technologies: Distribution by Type of Gene Delivery Modality
Figure 6.5 Genome Editing Technologies: Distribution by Highest Phase of Drug Development Supported
Figure 6.6 Genome Editing Technologies: Distribution by Therapeutic Area
Figure 6.7 Genome Editing Technologies: Distribution by Application Area
Figure 6.8 Genome Editing Technology Developers: Distribution by Year of Establishment
Figure 6.9 Genome Editing Technology Developers: Distribution by Company Size
Figure 6.10 Genome Editing Technology Developers: Distribution by Location of Headquarters
Figure 6.11 Genome Editing Technology Developers: Distribution by Company Size and Location of Headquarters
Figure 6.12 Genome Editing Technology Developers: Distribution by Operational Model
Figure 6.13 Genome Editing Technology Developers: Distribution by Product Centric Model
Figure 6.14 Genome Editing Technology Developers: Distribution by Technology Centric Model
Figure 6.15 Most Active Players: Distribution by Number of Technologies
Figure 7.1 Technology Competitiveness Analysis: Genome Editing Technologies Offered by players based in North America
Figure 7.2 Technology Competitiveness Analysis: Genome Editing Technologies Offered by players based in Europe
Figure 7.3 Technology Competitiveness Analysis: Genome Editing Technologies Offered by players based in Asia-pacific, Middle East and North Africa, and Latin America
Figure 8.1 Arcturus Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Figure 8.2 Beam Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Figure 8.3 Caribou Biosciences: Annual Revenues, FY 2020-H1 FY 2023 (USD Million)
Figure 8.4 Century Therapeutics: Annual Revenues, H1 FY 2022-H1 FY 2023 (USD Million)
Figure 8.5 CRISPR Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Figure 8.6 Editas Medicine: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Figure 8.7 Intellia Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Figure 9.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Technology Licensing / Integration Agreements: Distribution by Secondary Purpose of Partnership
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.6 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Figure 9.7 Most Active Players: Analysis by Number of Partnerships
Figure 9.8 Partnerships and Collaborations: Distribution by Region
Figure 9. Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 9.10 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2023
Figure 10.3 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 10.4 Patent Analysis: Distribution by Geography
Figure 10.5 Patent Analysis: Distribution by CPC Symbols
Figure 10.6 Leading Industry Players: Distribution by Number of Patents
Figure 10.7 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 10.8 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 10.9 Patent Analysis: Distribution by Patent Age
Figure 10.10 Patent Analysis: Valuation Analysis
Figure 11.1 Funding and Investments: Cumulative Year-wise Trend of Funding Instances, 2018-2023
Figure 11.2 Funding and Investments: Cumulative Year-wise Trend of Amount Invested, 2018-2023 (USD Million)
Figure 11.3 Funding and Investments: Distribution of Funding Instances by Type of Funding
Figure 11.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 11.5 Funding and Investments: Distribution of Funding Instances by Year and Type of Funding
Figure 11.6 Funding and Investments: Distribution of Funding Instances by Geography
Figure 11.7 Most Active Players: Distribution by Amount Invested and Number of Funding Instances
Figure 11.8 Leading Investors: Distribution by Number of Funding Instances
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
Figure 13.3 Global Genome Editing Technologies Market, Forecasted Estimates (2023-2035), Base Scenario (USD Billion)
Figure 13.4 Global Genome Editing Technologies Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Billion)
Figure 13.5 Global Genome Editing Technologies Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Billion)
Figure 14.1 Global Genome Editing Technologies Market: Distribution by Gene Editing Technique, 2023 and 2035 (USD Billion)
Figure 14.2 Genome Editing Technologies Market for CRISPR-Cas System, Forecasted Estimates (2023-2035) (USD Billion)
Figure 14.3 Genome Editing Technologies Market for TALENs, Forecasted Estimates (2023-2035) (USD Billion)
Figure 14.4 Genome Editing Technologies Market for Meganucleases, Forecasted Estimates (2023-2035) (USD Billion)
Figure 14.5 Genome Editing Technologies Market for ZFNs, Forecasted Estimates (2023-2035) (USD Billion)
Figure 14.6 Genome Editing Technologies Market for Other Techniques, Forecasted Estimates (2023-2035) (USD Billion)
Figure 15.1 Global Genome Editing Technologies Market: Distribution by Type of Therapy, 2023 and 2035 (USD Billion)
Figure 15.2 Genome Editing Technologies Market for Cell Therapies, Forecasted Estimates (2023-2035) (USD Billion)
Figure 15.3 Genome Editing Technologies Market for Gene Therapies, Forecasted Estimates (2023-2035) (USD Billion)
Figure 15.4 Genome Editing Technologies Market for Other Therapies, Forecasted Estimates (2023-2035) (USD Billion)
Figure 16.1 Global Genome Editing Technologies Market: Distribution by Gene Editing Approach, 2023 and 2035 (USD Billion)
Figure 16.2 Genome Editing Technologies Market for Knock-Out Approaches, Forecasted Estimates (2023-2035) (USD Billion)
Figure 16.3 Genome Editing Technologies Market for Knock-In Approaches, Forecasted Estimates (2023-2035) (USD Billion)
Figure 17.1 Global Genome Editing Technologies Market: Distribution by Gene Delivery Method, 2023 and 2035 (USD Billion)
Figure 17.2 Genome Editing Technologies Market for Ex-Vivo Delivery Methods, Forecasted Estimates (2023-2035) (USD Billion)
Figure 17.3 Genome Editing Technologies Market for In-Vivo Delivery Methods, Forecasted Estimates (2023-2035) (USD Billion)
Figure 18.1 Global Genome Editing Technologies Market: Distribution by Gene Editing Modality, 2023 and 2035 (USD Billion)
Figure 18.2 Genome Editing Technologies Market for Viral Vectors, Forecasted Estimates (2023-2035) (USD Billion)
Figure 18.3 Genome Editing Technologies Market for Non-Viral Vectors, Forecasted Estimates (2023-2035) (USD Billion)
Figure 19.1 Global Genome Editing Technologies Market: Distribution by Application Area, 2023 and 2035 (USD Billion)
Figure 19.2 Genome Editing Technologies Market for Drug Discovery and Development, Forecasted Estimates (2023-2035) (USD Billion)
Figure 19.3 Genome Editing Technologies Market for Diagnostics, Forecasted Estimates (2023-2035) (USD Billion)
Figure 20.1 Global Genome Editing Technologies Market: Distribution by Type of End User, 2023 and 2035 (USD Billion)
Figure 20.2 Genome Editing Technologies Market for Pharmaceutical and Biotechnology Companies, Forecasted Estimates (2023-2035) (USD Billion)
Figure 20.3 Genome Editing Technologies Market for Academic and Research Institutes, Forecasted Estimates (2023-2035) (USD Billion)
Figure 21.1 Global Genome Editing Technologies Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Billion)
Figure 21.2 Genome Editing Technologies Market in North America, Forecasted Estimates (2023-2035) (USD Billion)
Figure 21.3 Genome Editing Technologies Market in Europe, Forecasted Estimates (2023-2035) (USD Billion)
Figure 21.4 Genome Editing Technologies Market in Asia-Pacific, Forecasted Estimates (2023-2035) (USD Billion)
Figure 22.1 Global Genome Editing Technologies Market: Distribution by Type of Payment Method Employed, 2023 and 2035 (USD Billion)
Figure 22.2 Genome Editing Technologies Market for Milestone Payments, Forecasted Estimates (2023-2035) (USD Billion)
Figure 22.3 Genome Editing Technologies Market for Upfront Payments, Forecasted Estimates (2023-2035) (USD Billion)
Figure 24.1 Concluding Remarks: Overall Technology Landscape
Figure 24.2 Concluding Remarks: Partnerships and Collaborations
Figure 24.3 Concluding Remarks: Patent Analysis
Figure 24.4 Concluding Remarks: Funding and Investment Analysis
Figure 24.5 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 6.1 Genome Editing Technologies: Information on Type of Gene Editing Technique
Table 6.2 Genome Editing Technologies: Information on Technology Principle (in case of CRISPR-Cas System)
Table 6.3 Genome Editing Technologies: Information on Type of Gene Editing Approach
Table 6.4 Gene Editing Technologies: Information on In-silico (CADD) Analysis
Table 6.5 Genome Editing Technologies: Information on Type of Gene Delivery Method
Table 6.6 Genome Editing Technologies: Information on Type of Gene Delivery Modality
Table 6.7 Genome Editing Technologies: Information on Route of Administration
Table 6.8 Genome Editing Technologies: Information on Highest Phase of Drug Development Supported
Table 6.9 Genome Editing Technologies: Information on Therapeutic Area
Table 6.10 Genome Editing Technologies: Information on Application Area
Table 6.11 Genome Editing Technologies: List of Technology Developers
Table 6.12 Genome Editing Technology Developers: Information on Operational Model
Table 8.1 Genome Editing Technology Developers: List of Companies Profiled
Table 8.2 Arcturus Therapeutics: Company Overview
Table 8.3 Arcturus Therapeutics: Technology Portfolio
Table 8.4 Arcturus Therapeutics: Recent Developments and Future Outlook
Table 8.5 Beam Therapeutics: Company Overview
Table 8.6 Beam Therapeutics: Technology Portfolio
Table 8.7 Beam Therapeutics: Recent Developments and Future Outlook
Table 8.8 Caribou Biosciences: Company Overview
Table 8.9 Caribou Biosciences: Technology Portfolio
Table 8.10 Caribou Biosciences: Recent Developments and Future Outlook
Table 8.11 Century Therapeutics: Company Overview
Table 8.12 Century Therapeutics: Technology Portfolio
Table 8.13 Century Therapeutics: Recent Developments and Future Outlook
Table 8.14 CRISPR Therapeutics: Company Overview
Table 8.15 CRISPR Therapeutics: Technology Portfolio
Table 8.16 CRISPR Therapeutics: Recent Developments and Future Outlook
Table 8.17 Editas Medicine: Company Overview
Table 8.18 Editas Medicine: Technology Portfolio
Table 8.19 Editas Medicine: Recent Developments and Future Outlook
Table 8.20 Graphite Bio: Company Overview
Table 8.21 Graphite Bio: Technology Portfolio
Table 8.22 Graphite Bio: Recent Developments and Future Outlook
Table 8.23 Intellia Therapeutics: Company Overview
Table 8.24 Intellia Therapeutics: Technology Portfolio
Table 8.25 Intellia Therapeutics: Recent Developments and Future Outlook
Table 8.26 Prime Medicine: Company Overview
Table 8.27 Prime Medicine: Technology Portfolio
Table 8.28 Prime Medicine: Recent Developments and Future Outlook
Table 8.29 Vor Biopharma: Company Overview
Table 8.30 Vor Biopharma: Technology Portfolio
Table 8.31 Vor Biopharma: Recent Developments and Future Outlook
Table 8.32 Avectas: Company Overview
Table 8.33 Avectas: Technology Portfolio
Table 8.34 Bio-Sourcing: Company Overview
Table 8.35 Bio-Sourcing: Technology Portfolio
Table 8.36 Edigene: Company Overview
Table 8.37 Edigene: Technology Portfolio
Table 8.38 Flash Therapeutics: Company Overview
Table 8.39 Flash Therapeutics: Technology Portfolio
Table 8.40 Fortgen: Company Overview
Table 8.41 Fortgen: Technology Portfolio
Table 8.42 G+FLAS Life Sciences: Company Overview
Table 8.43 G+FLAS Life Sciences: Technology Portfolio
Table 8.44 Ntrans Technologies: Company Overview
Table 8.45 Ntrans Technologies: Technology Portfolio
Table 8.46 OXGENE: Company Overview
Table 8.47 OXGENE: Technology Portfolio
Table 8.48 Revvity (formerly known as Horizon Discovery): Company Overview
Table 8.49 Revvity (formerly known as Horizon Discovery): Technology Portfolio
Table 8.50 TargetGene Biotechnologies: Company Overview
Table 8.51 TargetGene Biotechnologies: Technology Portfolio
Table 8.52 ZeClinics: Technology Portfolio
Table 8.53 ZeClinics: Technology Portfolio
Table 9.1 Partnerships and Collaborations: Information on Year of Agreement, Type of Partnership, and Type of Partner, 2018-2023
Table 9.2 Technology Licensing / Integration Agreements: Information on Secondary Purpose of Partnership
Table 9.3 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Continent-wise), 2018-2023
Table 10.1 Patent Analysis: List of Top CPC Sections
Table 10.2 Patent Analysis: List of Top CPC Symbols
Table 10.3 Patent Analysis: List of Top CPC Codes
Table 10.4 Patent Analysis: Categorizations based on Weighted Valuation Scores
Table 10.5 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 11.1 Genome Editing Technologies: List of Funding and Investments
Table 13.1 Genome Editing Technologies: Average Upfront Payment and Average Milestone Payment, 2018-2023 (USD Million)
Table 26.1 Genome Editing Technologies: Distribution by Type of Gene Editing Technique
Table 26.2 Genome Editing Technologies: Distribution by Gene Editing Approach
Table 26.3 Genome Editing Technologies: Distribution by Type of Gene Delivery Method
Table 26.4 Genome Editing Technologies: Distribution by Type of Gene Delivery Modality
Table 26.5 Genome Editing Technologies: Distribution by Highest Phase of Drug Development Supported
Table 26.6 Genome Editing Technologies: Distribution by Therapeutic Area
Table 26.7 Genome Editing Technologies: Distribution by Application Area
Table 26.8 Genome Editing Technology Developers: Distribution by Year of Establishment
Table 26.9 Genome Editing Technology Developers: Distribution by Company Size
Table 26.10 Genome Editing Technology Developers: Distribution by Location of Headquarters
Table 26.11 Genome Editing Technology Developers: Distribution by Company Size and Location of Headquarters
Table 26.12 Genome Editing Technology Developers: Distribution by Operational Model
Table 26.13 Genome Editing Technology Developers: Distribution by Product Centric Model
Table 26.14 Genome Editing Technology Developers: Distribution by Technology Centric Model
Table 26.15 Most Active Players: Distribution by Number of Technologies
Table 26.16 Arcturus Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Table 26.17 Beam Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Table 26.18 Caribou Biosciences: Annual Revenues, FY 2020-H1 FY 2023 (USD Million)
Table 26.19 Century Therapeutics: Annual Revenues, H1 FY 2022-H1 FY 2023 (USD Million)
Table 26.20 CRISPR Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Table 26.21 Editas Medicine: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Table 26.22 Intellia Therapeutics: Annual Revenues, FY 2019-H1 FY 2023 (USD Million)
Table 26.23 Partnerships and Collaborations: Distribution by Type of Partnership
Table 26.24 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 26.25 Technology Licensing / Integration Agreements: Distribution by Secondary Purpose of Partnership
Table 26.26 Partnerships and Collaborations: Distribution by Type of Partner
Table 26.27 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Table 26.28 Most Active Players: Analysis by Number of Partnerships
Table 26.29 Partnerships and Collaborations: Distribution by Region
Table 26.30 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Table 26.31 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 26.32 Patent Analysis: Distribution by Type of Patent
Table 26.33 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2023
Table 26.34 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 26.35 Patent Analysis: Distribution by Geography
Table 26.36 Patent Analysis: Distribution by CPC Symbols
Table 26.37 Leading Industry Players: Distribution by Number of Patents
Table 26.38 Funding and Investments: Cumulative Year-wise Trend of Funding Instances, 2018-2023
Table 26.39 Funding and Investments: Cumulative Year-wise Trend of Amount Invested, 2018-2023 (USD Million)
Table 26.40 Funding and Investments: Distribution of Funding Instances by Type of Funding
Table 26.41 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Table 26.42 Funding and Investments: Distribution of Funding Instances by Year and Type of Funding
Table 26.43 Funding and Investments: Distribution of Funding Instances by Geography
Table 26.44 Most Active Players: Distribution by Amount Invested and Number of Funding Instances
Table 26.45 Leading Investors: Distribution by Number of Funding Instances
Table 26.46 Global Genome Editing Technologies Market, Forecasted Estimates (2023-2035), Base Scenario (USD Billion)
Table 26.47 Global Genome Editing Technologies Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Billion)
Table 26.48 Global Genome Editing Technologies Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Billion)
Table 26.49 Global Genome Editing Technologies Market: Distribution by Gene Editing Technique, 2023 and 2035 (USD Billion)
Table 26.50 Genome Editing Technologies Market for CRISPR-Cas System, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.51 Genome Editing Technologies Market for TALENs, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.52 Genome Editing Technologies Market for Meganucleases, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.53 Genome Editing Technologies Market for ZFNs, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.54 Genome Editing Technologies Market for Other Techniques, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.55 Global Genome Editing Technologies Market: Distribution by Type of Therapy, 2023 and 2035 (USD Billion)
Table 26.56 Genome Editing Technologies Market for Cell Therapies, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.57 Genome Editing Technologies Market for Gene Therapies, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.58 Genome Editing Technologies Market for Other Therapies, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.59 Global Genome Editing Technologies Market: Distribution by Gene Editing Approach, 2023 and 2035 (USD Billion)
Table 26.60 Genome Editing Technologies Market for Knock-Out Approaches, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.61 Genome Editing Technologies Market for Knock-In Approaches, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.62 Global Genome Editing Technologies Market: Distribution by Gene Delivery Method, 2023 and 2035 (USD Billion)
Table 26.63 Genome Editing Technologies Market for Ex-Vivo Delivery Methods, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.64 Genome Editing Technologies Market for In-Vivo Delivery Methods, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.65 Global Genome Editing Technologies Market: Distribution by Gene Editing Modality, 2023 and 2035 (USD Billion)
Table 26.66 Genome Editing Technologies Market for Viral Vectors, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.67 Genome Editing Technologies Market for Non-Viral Vectors, Forecasted Estimates (2023-2035) (USD Billion)
Table 26.68 Global Genome Editing Technologies Market: Distribution by Application Area, 2023 and 2035 (USD Billion)
Table 26.69 Genome Editing Technologies Market for Drug Discovery and Development, Forecasted

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 2seventy bio
  2. 5AM Ventures
  3. 683 Capital
  4. AbbVie
  5. Abcam
  6. Acrigen Biosciences
  7. Acuitas Therapeutics
  8. Myllia Biotechnology (formerly known as Aelian Biotechnology)
  9. Affini-T Therapeutics
  10. Aju IB Investments
  11. Akribion Genomics
  12. Aldevron
  13. Alexion Pharmaceuticals
  14. Alia Therapeutics 
  15. Allogene Therapeutics
  16. Ally Bridge Group
  17. Almirall
  18. Altitude Life Science Ventures
  19. Altium Capital
  20. Amgen Ventures
  21. Andreessen Horowitz
  22. AnGes
  23. Ankarys Therapeutics
  24. ANLBIO
  25. APEIRON Biologics
  26. Apellis Pharmaceuticals
  27. Applied Biological Materials
  28. Applied StemCell
  29. Arbor Biotechnologies
  30. ARCH Venture Partners
  31. Arctoris
  32. Arcturus Therapeutics
  33. Arix Bioscience
  34. Armistice Capital
  35. ArrowMark Partners
  36. ArsenalBio
  37. Artisan Bio
  38. Asahi Kasei Corporate Venture Capital
  39. Ascenion
  40. Asklepios BioPharmaceutical
  41. Astellas Pharma
  42. AstraZeneca
  43. ATCC
  44. ATLATL Innovation Centre
  45. Avectas
  46. Novartis Gene Therapies (formerly known as AveXis)
  47. Avoro Capital Advisors
  48. Avoro Ventures
  49. Axcelead
  50. Axxam
  51. Bain Capital Life Sciences
  52. Bayer
  53. Beam Therapeutics 
  54. Bill & Melinda Gates Foundation
  55. Bio Palette
  56. Biocytogen
  57. Biogen
  58. Bioluminescence Ventures
  59. Biomedical Advanced Research and Development Authority (BARDA)
  60. Bioneer
  61. Bio-Sourcing
  62. Blink Therapeutics
  63. BlueRock Therapeutics
  64. BOP Capital
  65. Boston Children's Hospital
  66. Boxer Capital
  67. BRAIN Biotech
  68. BrainXell
  69. Branca Bunús
  70. BrightPath Biotherapeutics
  71. Bristol-Myers Squibb
  72. Broad Institute of MIT and Harvard
  73. Brookhaven Bio
  74. Byers Capital
  75. C4U
  76. C4X Discovery
  77. CaaS Capital
  78. Cabaletta Bio
  79. California Institute for Regenerative Medicine (CIRM)
  80. Canaccord Genuity
  81. CANbridge Pharmaceuticals
  82. Capsida Biotherapeutics
  83. Capstan Therapeutics
  84. Caribou Biosciences
  85. Cartherics
  86. CasCure Therapeutics
  87. Casdin Capital
  88. Caszyme
  89. Catalent
  90. Catalio Capital Management
  91. Catamaran Bio
  92. CCRM
  93. CD Capital
  94. Cellecta
  95. Cellectis
  96. CellFE
  97. Celularity
  98. Center for Breakthrough Medicines
  99. Central Institute for Experimental Animals (CIEA)
  100. Century Therapeutics
  101. CF Foundation
  102. CHA Research Institute
  103. CHA Biotech
  104. Charcot-Marie-Tooth Association
  105. China Life Healthcare Fund
  106. ChristianaCare
  107. Cimeio Therapeutics
  108. Clairvoyant Ventures
  109. CMB International Capital Holdings
  110. Cormorant Asset Management
  111. CorriXR Therapeutics
  112. Cosmo Bio
  113. Cota Capital
  114. Couragene
  115. Cowen Healthcare Investments
  116. CPE
  117. Creative Biogene
  118. CRISP-HR Therapeutics
  119. CRISPR Biotech Engineering
  120. Crispr Stem & Therapeutics
  121. CRISPR Therapeutics
  122. Crown Bioscience
  123. CSL Seqirus
  124. Curamys
  125. Curia
  126. CyGenica
  127. Cystic Fibrosis Foundation
  128. Cytosurge
  129. Cytovia Therapeutics
  130. D1 Capital Partners
  131. Daiichi Sankyo
  132. Danaher
  133. DCI Partners
  134. Decheng Capital
  135. DefiniGEN
  136. Delos Capital
  137. Duke University School of Medicine
  138. Duke-NUS Medical School
  139. Dynamk Capital
  140. EcoR1 Capital
  141. EdiGene
  142. Editas Medicine
  143. eGenesis
  144. Elaia Partners
  145. Eledon Pharmaceuticals
  146. Eli Lilly
  147. Emendo Biotherapeutics 
  148. Emerson Collective
  149. Empirica
  150. Ennovation Ventures
  151. Ensoma
  152. EPIQ Capital Group
  153. ERS Genomics
  154. ETP Ventures
  155. Euclidean Capital
  156. Eurofins
  157. European Innovation Council (EIC)
  158. European Investment Bank
  159. EV Biologics
  160. Evercrisp Biosciences
  161. Evotec
  162. Excision BioTherapeutics
  163. Exothera
  164. Farallon Capital
  165. FASMAC
  166. Feldan Therapeutics
  167. Flash Therapeutics
  168. Foresite Capital
  169. Fortgen
  170. F-Prime Capital
  171. Fresenius Medical Care Ventures (FMCV)
  172. Friedreich’s Ataxia Research Alliance (FARA)
  173. FUJIFILM Cellular Dynamics
  174. Future Fields
  175. G+FLAS Life Sciences
  176. GC Cell
  177. GEcoll Biomedical
  178. GEMoaB
  179. GenAhead Bio
  180. GeneLancet Biosciences
  181. Genentech
  182. GENETAGUS
  183. Genethon
  184. Genexine
  185. GenKOre
  186. GenNBio
  187. genOway
  188. GenScript
  189. German Center for Neurodegenerative Diseases (DZNE)
  190. Gilead Sciences
  191. GL Ventures
  192. GordonMD Global Investments
  193. Graphite Bio
  194. GreatPoint Ventures
  195. Green Cross LabCell 
  196. Green Sands
  197. Gritstone Oncology
  198. GrittGene Therapeutics
  199. GSK Consumer Healthcare
  200. Guide Therapeutics (a subsidiary of Beam Therapeutics)
  201. Haihe Laboratory of Cell Ecosystem
  202. Hamburg Investment and Development Bank
  203. Hangzhou Huixin Biotechnology
  204. Hansa Biopharma
  205. Harvard University
  206. Hatteras Investment Partners
  207. HBM Healthcare Investments
  208. HebeCell
  209. Heights Capital
  210. Hera Biolabs
  211. Hercules Capital
  212. Hitachi Ventures
  213. Horizon Technology Finance
  214. Hunterian Medicine
  215. IDG Capital
  216. iECURE
  217. Illumina
  218. Immatics
  219. Immunochina
  220. In Vivo Biosystems (formerly known as NemaMetrix)
  221. Inceptor Bio
  222. Incisive Genetics
  223. Infinome Biosciences
  224. Inhibrx
  225. Innovation Agency
  226. Innovationsstarter Fonds Hamburg
  227. Inscripta
  228. Intellia Therapeutics
  229. Intima Bioscience
  230. Invesco Asset Management
  231. Investissement Québec
  232. Invus
  233. Ionis Pharmaceuticals
  234. Iovance Biotherapeutics
  235. Irving Investors
  236. Israeli Ministry of Health
  237. JAFCO
  238. Janssen Biotech
  239. Japan SLC
  240. Jasper Therapeutics
  241. Jenthera Therapeutics
  242. JS Capital Management
  243. JW Therapeutics
  244. Karius
  245. Kite Pharma
  246. Kiwoom Investment
  247. Kleiner Perkins
  248. KRYSP-R
  249. KSQ Therapeutics
  250. Kyverna Therapeutics
  251. Lake Bleu Capital
  252. Lapam Capital
  253. Leaps by Bayer
  254. Lepton Pharmaceuticals
  255. LG Chem
  256. Life Edit Therapeutics
  257. LifeSci Venture Partners
  258. Lilly Asia Venture
  259. LogicBio Therapeutics
  260. Longmen Capital
  261. Lonza
  262. Loyal Valley Capital
  263. Lyell Immunopharma
  264. LYFE Capital
  265. MacHall Group
  266. Macrogen
  267. Madison Avenue Partners
  268. Magenta Therapeutics
  269. Makana Therapeutics
  270. Mammoth Biosciences
  271. Matrix Partners China
  272. Maxcyte
  273. Mayfield
  274. Mayo Clinic
  275. Memorial Sloan Kettering Cancer Center
  276. Mercia
  277. Merck
  278. Mérieux Développement
  279. Metagenomi
  280. Micro CRISPR 
  281. MidCap Financial
  282. Mind the Byte
  283. Mizuho Securities
  284. Modalis Therapeutics
  285. Moderna
  286. Mogrify
  287. Monashee Investment Management
  288. Moogene Medi
  289. Morningside Ventures
  290. Myeloid Therapeutics
  291. Nanjing Bioheng Biotech
  292. National Institutes of Health (NIH)
  293. National Science Foundation
  294. Nephrogen
  295. Neukio Biotherapeutics
  296. New England Biolabs
  297. Kite Ventures
  298. New South Wales Government
  299. Newpath Partners
  300. Newtyn Management
  301. Nippon Gene
  302. Nkarta
  303. Noile-Immune Biotech
  304. Novartis
  305. Novo Holdings
  306. Novo Nordisk
  307. Ntrans Technologies
  308. NUVISAN ICB
  309. Nvelop Therapeutics
  310. Oak HC/FT
  311. Octagon Capital
  312. ONK Therapeutics
  313. Orbital Therapeutics
  314. Osage University Partners
  315. Otsuka Pharmaceutical
  316. Outpace Bio
  317. Oxford Finance
  318. OXGENE
  319. Paladin Capital
  320. PanCELLa
  321. Pangen Biotech
  322. Panmure Gordon
  323. Pantherna Therapeutics
  324. Parker Institute for Cancer Immunotherapy (PICI)
  325. Peking Union Medical College Hospital
  326. Peking University Cancer Hospital
  327. Pencil Biosciences
  328. Perceptive Advisors
  329. Pfizer
  330. PFM Health Sciences
  331. Phen Vista
  332. Pluristyx
  333. Polaris Partners
  334. Polyplus-transfection
  335. Precision BioSciences
  336. Prevail Therapeutics
  337. Prime Medicine
  338. Primera Therapeutics
  339. Primordial Genetics
  340. ProBioGen
  341. Promega
  342. Prorenata Biotech
  343. PROVIREX Genome Editing Therapies
  344. Qihan Biotech
  345. QUIDDITAS Therapeutics
  346. RA Capital Management
  347. Recipharm
  348. ReCode Therapeutics
  349. Recombinetics
  350. Red Tree Venture Capital
  351. Redmile Group
  352. Reforgene Medicine
  353. Rege Nephro
  354. Regeneron
  355. Resilience
  356. Revvity (formerly known as Horizon Discovery) 
  357. Rewrite Therapeutics
  358. Ridgeback Capital Investments
  359. Rock Springs Capital
  360. RTW Investments
  361. Rutgers University
  362. Samsara BioCapital
  363. Sana Biotechnology
  364. Sandhill Therapeutics
  365. Sangamo Therapeutics
  366. Sanofi
  367. Santa Cruz Biotechnology
  368. Sanzheng Health Investment
  369. Scottish Enterprise
  370. Scribe Therapeutics
  371. SDIC Venture Capital
  372. SE Therapeutics
  373. Seamus Mulligan
  374. Seattle Children’s Research Institute
  375. Sequoia Capital China
  376. Sestina Bio
  377. Setsuro Tech
  378. Shanghai BDgene Technology
  379. Shoreline Biosciences
  380. Silicon Valley Bank
  381. Simcere Pharmaceuticals
  382. Singapore Economic Development Board (EDB)
  383. SJ Investment Partners
  384. SML Genetree
  385. Sofinnova Partners
  386. Solana Biosciences
  387. Songhe Capital
  388. SOSV
  389. SparingVision
  390. Sphere Fluidics
  391. Spotlight Therapeutics
  392. SpringWorks Therapeutics
  393. Starfish Innovations
  394. Stellate DNA
  395. STIC Ventures
  396. Stifel
  397. Strongest Hearts Foundation
  398. Sumitomo
  399. SymBiosis
  400. Syngulon
  401. Synthego
  402. T&R Biofab
  403. Takara Bio
  404. Takeda Pharmaceuticals
  405. TargetGene Biotechnologies
  406. Taros Chemicals
  407. TCG Crossover
  408. TCR² Therapeutics
  409. TechLife Capital
  410. Temasek
  411. Teneobio
  412. The Wells Investment
  413. Thermo Fisher Scientific
  414. Tiziana Life Sciences
  415. T-MAXIMUM Biotech
  416. Tofflon
  417. ToolGen
  418. TPG Capital
  419. TransCode Therapeutics
  420. Transomic Technologies
  421. TransViragen
  422. Trentino Invest
  423. Tsinghua Holdings Capital
  424. Twelve Bio (a subsidiary of Ensoma)
  425. Twist Bioscience
  426. TxCell
  427. University of Bern
  428. University of California
  429. University of California San Francisco
  430. University of Edinburg
  431. University of Miami
  432. University of North Carolina
  433. University of Pennsylvania
  434. University of Wisconsin-Madison
  435. Versant Ventures
  436. Vertex Pharmaceuticals
  437. Verve Therapeutics
  438. Vesigen Therapeutics
  439. ViaCyte
  440. Vida Ventures
  441. Vingroup
  442. VirEdit Biosciences
  443. Viromer Transfection
  444. Virostem Biotechnology
  445. viTToria Biotherapeutics
  446. VivaZome Therapeutics
  447. Vivlion
  448. Vor Biopharma
  449. Voyager Therapeutics
  450. Walking Fish Therapeutics
  451. Wellington Management
  452. Western Alliance Bank
  453. Westlake Village BioPartners
  454. WuXi AppTec
  455. Yaotang (Shanghai) Biotechnology
  456. Yuansheng Venture Capital
  457. ZeClinics
  458. Zhejiang University

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com